Boardroom Alpha
Start trial
10-K primary document
TARS · Annual Report (Form 10-K) · Filed February 23, 2026

Tarsus Pharmaceuticals Inc — 10-K exhibit

exhibit231202510k.htm
Tarsus Pharmaceuticals Inc on Boardroom Alpha
Document

Exhibit 23.1
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-249571) pertaining to the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan, the Tarsus Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan, and the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan of Tarsus Pharmaceuticals, Inc.,
(2) Registration Statement (Form S-8 No. 333-254932) pertaining to the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan, and the Tarsus Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan of Tarsus Pharmaceuticals, Inc.,
(3) Registration Statement (Form S-8 No. 333-263537) pertaining to the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan and the Tarsus Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan of Tarsus Pharmaceuticals, Inc.,
(4) Registration Statement (Form S-8 No. 333-270644) pertaining to the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan and Tarsus Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan of Tarsus Pharmaceuticals, Inc.,
(5) Registration Statement (Form S-8 No. 333-277400) pertaining to the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan of Tarsus Pharmaceuticals, Inc.,
(6) Registration Statement (Form S-8 No. 333-285201) pertaining to the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan and the Tarsus Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan of Tarsus Pharmaceuticals, Inc.;
(7) Registration Statement (Form S-3 No. 333-275439) of Tarsus Pharmaceuticals, Inc., and;
(8) Registration Statement (Form S-3ASR No. 333-277523) of Tarsus Pharmaceuticals, Inc.;

of our reports dated February 23, 2026 with respect to the financial statements of Tarsus Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Tarsus Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Tarsus Pharmaceuticals, Inc. for the year ended December 31, 2025.
/s/ Ernst & Young LLP

Irvine, California

February 23, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer